Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6HIG

hPD-1/NBO1a Fab complex

Summary for 6HIG
Entry DOI10.2210/pdb6hig/pdb
DescriptorHeavy Chain, Light Chain, Programmed cell death protein 1, ... (4 entities in total)
Functional Keywordsnon-blocking antibody, pd-1/pd-l1 pathway, anti-pd-1 antibody, tumor clearance, immune system
Biological sourceMus musculus
More
Total number of polymer chains3
Total formula weight61731.74
Authors
Loredo-Varela, J.L.,Fenwick, C.,Pantaleo, G.,Weissenhorn, W. (deposition date: 2018-08-29, release date: 2019-06-05, Last modification date: 2024-10-23)
Primary citationFenwick, C.,Loredo-Varela, J.L.,Joo, V.,Pellaton, C.,Farina, A.,Rajah, N.,Esteves-Leuenberger, L.,Decaillon, T.,Suffiotti, M.,Noto, A.,Ohmiti, K.,Gottardo, R.,Weissenhorn, W.,Pantaleo, G.
Tumor suppression of novel anti-PD-1 antibodies mediated through CD28 costimulatory pathway.
J.Exp.Med., 216:1525-1541, 2019
Cited by
PubMed Abstract: Classical antagonistic antibodies (Abs) targeting PD-1, such as pembrolizumab and nivolumab, act through blockade of the PD-1-PDL-1 interaction. Here, we have identified novel antagonistic anti-PD-1 Abs not blocking the PD-1-PDL-1 interaction. The nonblocking Abs recognize epitopes on PD-1 located on the opposing face of the PDL-1 interaction and overlap with a newly identified evolutionarily conserved patch. These nonblocking Abs act predominantly through the CD28 coreceptor. Importantly, a combination of blocking and nonblocking Abs synergize in the functional recovery of antigen-specific exhausted CD8 T cells. Interestingly, nonblocking anti-PD-1 Abs have equivalent antitumor activity compared with blocker Abs in two mouse tumor models, and combination therapy using both classes of Abs enhanced tumor suppression in the mouse immunogenic tumor model. The identification of the novel nonblocker anti-PD-1 Abs and their synergy with classical blocker Abs may be instrumental in potentiating immunotherapy strategies and antitumor activity.
PubMed: 31123083
DOI: 10.1084/jem.20182359
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.2 Å)
Structure validation

246905

PDB entries from 2025-12-31

PDB statisticsPDBj update infoContact PDBjnumon